Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal.

Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal.
复制标题

需要住院的实体器官移植受者中Nirmatrelvir/Ritonavir的超治疗他克莫司浓度:使用利福平治疗的病例系列。

DOI:
10.1093/ofid/ofac238
复制
发表时间:
2022-07
影响因子:
4.2
通讯作者:
--
中科院分区:
医学3区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

Nirmatrelvir/ritonavir最近获得了2019年轻度至中度冠状病毒病的紧急使用授权。利托那韦和他克莫司之间的药物相互作用被非移植提供者低估。我们描述了2例实体器官移植受者,处方Nirmatrelvir/利托那韦门诊使用谁开发他克莫司毒性需要住院治疗,并与利福平的毒性逆转管理。
Nirmatrelvir/ritonavir was recently granted emergency use authorization for mild to moderate coronavirus disease 2019. Drug–drug interactions between ritonavir and tacrolimus are underappreciated by nontransplant providers. We describe 2 solid organ transplant recipients prescribed nirmatrelvir/ritonavir for outpatient use who developed tacrolimus toxicity requiring hospitalization and were managed with rifampin for toxicity reversal.
DOI: 10.1177/00912709922007499
发表时间: 1999-01-01
影响因子: 2.9
作者:
Hebert, MF;Fisher, RM;Bekersky, I
通讯作者: Bekersky, I
DOI: 10.1111/ajt.16364
发表时间: 2021-05
期刊: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
影响因子: --
作者:
通讯作者: --
DOI: 10.1038/clpt.2011.164
发表时间: 2011-11-01
影响因子: 6.7
作者:
Katzenmaier, S.;Markert, C.;Mikus, G.
通讯作者: Mikus, G.
DOI: 10.1111/tid.13388
发表时间: 2020-07-10
影响因子: 2.6
作者:
Thammathiwat, Theerachai;Tungsanga, Somkanya;Townamchai, Natavudh
通讯作者: Townamchai, Natavudh
DOI: 10.1111/ajt.13111
发表时间: 2015-05
期刊: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
影响因子: --
作者:
Badri P;Dutta S;Coakley E;Cohen D;Ding B;Podsadecki T;Bernstein B;Awni W;Menon R
通讯作者: Menon R